Tumor-infiltrating lymphocyte (TIL) therapy — an adoptive cell therapy approach in which autologous lymphocytes are harvested from resected tumor tissue, expanded ex vivo, and reinfused into lymphodepleted patients — represents one of the most clinically validated cellular immunotherapy platforms for solid tumors. Retrieved results highlight three primary solid tumor indications dominating TIL therapy research: metastatic melanoma, advanced cervical cancer, and non-small cell lung cancer (NSCLC).

Across these indications, critical molecular and immunological targets include tumor-associated neoantigens recognized by polyclonal TIL populations, the PD-1/PD-L1 immune checkpoint axis, CTLA-4, TCR clonotypes linked to tumor reactivity, and cytokines — particularly interleukin-2 (IL-2) — that sustain TIL viability and expansion.

The high tumor mutation burden (TMB) of melanoma is identified as a key rationale for TIL therapy's early clinical success in this indication, with diverse TCR clonality enabling multi-epitope coverage of mutational neoantigens. For cervical cancer, HPV-driven tumor antigen expression provides the mechanistic rationale for TIL-based approaches, representing the first common epithelial tumor in which TIL adoptive transfer demonstrated meaningful activity.

Clonal neoantigens — mutations present in all tumor cells rather than subclones — are identified as critical targets for next-generation TIL products in NSCLC, where subclonal heterogeneity limits therapeutic efficacy. PD-1 and PD-L1 feature prominently as both therapeutic targets and modulators of TIL function within the tumor microenvironment (TME).

Retrieved results signal several convergent combination and next-generation strategies across the TIL therapy pipeline. The most clinically developed combination pairs TIL with checkpoint inhibitors (PD-1/CTLA-4 blockade). Signals suggest that ipilimumab administered prior to tumor resection enhances TIL product quality, while post-infusion nivolumab sustains TIL function in vivo — a mechanistically coherent design supported by both clinical and preclinical evidence.

The Netherlands Cancer Institute study demonstrates via CyTOF mass cytometry (38 markers) that PD-L1 blockade drives TIL upregulation of co-expressed activating and inhibitory receptors, informing rational combination design. This preclinical mechanism directly supports the Copenhagen Phase I/II trial's clinical design of sequential ipilimumab (pre-harvest) and nivolumab (post-infusion).

Retrieved results also signal a trajectory toward personalized TIL products enriched for clonal neoantigen reactivity, particularly in NSCLC. Technologies cited include pMHC multimer staining and cytokine capture sorting prior to expansion — representing a fundamentally different manufacturing paradigm than current unselected TIL protocols. Access the full life sciences pipeline intelligence on PatSnap.

Iovance patent data describes evaluation of IL-2/IL-15/IL-21 combinations to enhance TIL functional capacity (CD107a degranulation, IFN-γ secretion) without the toxicity of high-dose IL-2 — signaling a manufacturing-level trend toward reduced cytokine toxicity. The Copenhagen trial used low-dose IL-2 (2×10⁶ IU subcutaneous ×14 days) post-infusion, indicating a trend toward reduced-toxicity IL-2 schedules. Explore the full patent analytics for cytokine optimization strategies.